Atomi Financial Group Inc. reduced its position in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by ...

Shares of Charles River Laboratories International Inc. CRL slipped 1.13% to $164.97 Friday, on what proved to be an ...

William Blair analysts downgraded shares of Charles River Laboratories International Inc. (NYSE:CRL) stock from Outperform to ...

Crossmark Global Holdings Inc. lowered its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free ...

At the JP Morgan Healthcare Conference 2025, Charles River CEO blamed low client spending, loss of a contract and other ...

William Blair downgraded Charles River Laboratories to market perform citing concerns over a decline in early-stage R&D funding from large pharmas. Read more here.

Upslope Capital Management, an investment management firm, released its fourth-quarter 2024 investor letter. A copy of the ...

Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2024 investor letter. A ...

Analysts have recently evaluated Charles River and provided 12-month price targets. The average target is $214.5, accompanied by a high estimate of $250.00 and a low estimate of $185.00. A 2.72% drop ...

Shares for Charles River Laboratories slipped after the company said it expects revenue to decline in 2025. Shares of the Massachusetts-based pharmaceutical company were recently down 6% to $178.50 in ...

William Blair downgraded Charles River (CRL) to Market Perform from Outperform.Invest with Confidence: Follow TipRanks' Top Wall Street ...

Mizuho Securities analyst Ann Hynes has maintained their neutral stance on CRL stock, giving a Hold rating yesterday.Stay Ahead of the ...